GoodRx (NASDAQ:GDRX) Reaches New 52-Week Low After Analyst Downgrade

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) reached a new 52-week low during mid-day trading on Wednesday after Citigroup lowered their price target on the stock from $10.00 to $7.00. Citigroup currently has a buy rating on the stock. GoodRx traded as low as $4.61 and last traded at $4.63, with a volume of 871841 shares trading hands. The stock had previously closed at $4.70.

GDRX has been the topic of a number of other reports. Barclays cut their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price on the stock in a research note on Friday, August 9th. UBS Group cut their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.86.

Insider Buying and Selling at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 4.17% of the company’s stock.

Institutional Investors Weigh In On GoodRx

Several institutional investors have recently made changes to their positions in the company. Cornercap Investment Counsel Inc. lifted its holdings in shares of GoodRx by 1.7% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock valued at $587,000 after buying an additional 1,266 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of GoodRx by 5.1% during the 1st quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock valued at $503,000 after buying an additional 3,444 shares during the last quarter. US Bancorp DE lifted its holdings in shares of GoodRx by 3.7% during the 1st quarter. US Bancorp DE now owns 109,818 shares of the company’s stock valued at $780,000 after buying an additional 3,877 shares during the last quarter. Beacon Capital Management LLC acquired a new stake in shares of GoodRx during the 1st quarter valued at about $28,000. Finally, nVerses Capital LLC acquired a new stake in shares of GoodRx during the 3rd quarter valued at about $33,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Trading Down 2.1 %

The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -155.33, a price-to-earnings-growth ratio of 3.24 and a beta of 1.39. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a fifty day moving average price of $6.69 and a 200-day moving average price of $7.46.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.